glutathione and dopamine parkinson's disease clinical trial Phase 1/2a of hESC-derived progenitors in disease: Cell Glutathione & Parkinson's: Evidence, Biomarkers, – Parkinson's Disease Treatment | IV

What Changed in the Last 24 Hours On April 22, 2026 , the FDA Law Blog published Post 2 of 2 in its peptide compounding series

Immune modulation adjusts the balance between different immune pathways, ideally suppressing the overactive autoimmune responses while preserving or even enhancing protective immunity

Since gain-of-function mutations in NLRP3 were demonstrated to cause a rare autoinflammatory disease termed cryopyrin-associated periodic syndrome, NLRP3 has emerged as key mediator of inflammation in mouse models for many common diseases, including atherosclerosis, Alzheimers disease and gout

On the left is a diagram from a BPC-157 study and on the right from our in-vitro platelet-based tendon healing study (5)